ArticleOpen life sciences2026

Real-world validation of ECOG performance status and neutrophil-to-lymphocyte ratio in second-line paclitaxel plus ramucirumab for advanced gastric cancer.

Hong Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.